Genetic screening for haematological cancers

Screening for haematological cancers is costly and time-consuming. The standard screening procedure, which looks for mutations in four specific genes, costs about $300 and can take seven to 10 days to return complete results. To allay the costs involved, many hospitals wait for a batch of samples from multiple patients before running the test. Precipio, based in New Haven, has now advanced the state of care with the commercial launch of HemeScreen, a novel proprietary test for mutations in haematological cancers.

Importantly, the HemeScreen assay can deliver results in four to six hours rather than days, enabling a same-day turnaround time. Equally important, the HemeScreen assay also costs a fraction of the current technologies to run. At $100, this is about one-third of the cost of the traditional method, making the potential savings substantial.

 

Other news

Upcoming Events

HUCBMS 2019

Technological University Dublin
3-4 September 2019

The Oxford Haematology in Obstetrics Postgraduate Course

St Edmund Hall, Queen's Lane, Oxford OX1 4AR
9-11 September 2019

IBMS Biomedical Science Congress

ICC, Birmingham
22-25 September 2019

Lab Innovations

NEC, Birmingham (Hall 12)
30 & 31 October 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Aug 2019

Meet Epredia: introducing a team you already know

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.